SCHEMBL19965713

SCHEMBL19965713

CCCC(C)(C)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
TRPV1 Q8NER1 2/20 0.42
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.41
CCR6 P51684 1/20 0.40
NOS3 P29474 2/20 0.40
NOS1 P29475 2/20 0.40
NOS2 P35228 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KIF11 P52732 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
PDE2A O00408 1/20 0.39
POLB P06746 1/20 0.39
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22024859 0.89 HDAC3 (0.48) HDAC3HDAC1HDAC2EPHX2NR1H4
SCHEMBL17552746 0.85 NPC1 (0.55) HDAC3HDAC1HDAC2EPHX2NR1H4
SCHEMBL20866437 0.82 HDAC3 (0.41) HDAC3HDAC1HDAC2EPHX2NR1H4
SCHEMBL18737497 0.81 KIF11 (0.47) L3MBTL1KIF11SCN10ACNR2
SCHEMBL25875768 0.80 NPC1 (0.37) NPC1MAPTRAB9ACNR2
SCHEMBL23616384 0.80 CNR2 (0.44) NPC1MAPTRAB9ACNR2
SCHEMBL22096344 0.80 KIF11 (0.46) EPHX2NR1H4CCR6KIF11NPC1
SCHEMBL8507750 0.79 SCN10A (0.52) EPHX2NR1H4TRPV1TSHRNOS3
SCHEMBL9559033 0.79 EPHX2 (0.47) HDAC3HDAC1HDAC2EPHX2NR1H4
SCHEMBL20181956 0.79 HDAC3 (0.48) HDAC3HDAC1HDAC2EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210179600-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 Hepagene Therapeutics (HK) Limited (HK) 2021-06-17 US disclosed
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-22 US disclosed
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT HDAC3 236/4885HDAC1 75/4885HDAC2 57/4885
US-20210179600-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 IRAK1, IRAK2, IRAK3 HDAC3 889/4885HDAC1 279/4885HDAC2 984/4885
US-20180072660-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT HDAC3 236/4885HDAC1 75/4885HDAC2 57/4885
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT HDAC3 236/4885HDAC1 75/4885HDAC2 57/4885
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT HDAC3 236/4885HDAC1 75/4885HDAC2 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.